ORPHA:41751
Bietti crystalline dystrophy
Also known as: BCD · Bietti crystalline corneoretinal dystrophy · Bietti crystalline retinopathy
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
356
83.1th percentile
Trials
9
Interventional, condition-specific
Researchers
999
Distinct authors in sample
Gene link
CYP4V2
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare tapetoretinal degeneration disease, occurring in the third decade of life, characterized by small sparkling crystalline deposits in the posterior retina and corneal limbus in addition to sclerosis of the choroidal vessels and manifesting as nightblindness, decreased vision, paracentral scotoma, and, in the end stages of the disease, legal blindness.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008865
- MeSH:C535440
- OMIM:210370
- UMLS:C1859486
- NCIT:C179299
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — CYP4V2
- LiteraturePresent
356 matched papers (270 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
9 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (CYP4V2).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
356
356 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
356 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
270 in the last 10 years · medium confidence · 83.1th percentile (publications denominator)
Phrase hits: 356 · MeSH hits: 0
Who's working on it?
999
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li Y13 papers · 2026
Tongren Eye Center, Beijing key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology&Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Papers in Europe PMC - 02Liu Y12 papers · 2026
The Physical Examination Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, China.
Papers in Europe PMC - 03Wang J12 papers · 2026
Department of Ophthalmology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing 100730, China.
Papers in Europe PMC - 04Li H11 papers · 2026
Department of Ophthalmology, Peking Union Medical College Hospital, Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Papers in Europe PMC - 05Yang L10 papers · 2026
Department of Ophthalmology, Peking University Third Hospital, Beijing, 100191, China. alexlipingyang@bjmu.edu.cn.
Papers in Europe PMC - 06Liu X9 papers · 2026
Department of Ophthalmology, Peking University Third Hospital, Beijing, 100191, China.
Papers in Europe PMC - 07Wang L9 papers · 2026
Hebei Provincial Key Laboratory of Ophthalmology, Hebei Provincial Eye Institute, Hebei Provincial Eye Hospital, 399 East Quanbei Street, Xingtai, 054001, Hebei, People's Republic of China.
Papers in Europe PMC - 08Yu S9 papers · 2026
Department of Ophthalmology, Peking University Third Hospital, Beijing, 100191, China.
Papers in Europe PMC - 09Zhang H9 papers · 2026
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
Papers in Europe PMC - 10Li Q8 papers · 2026
Department of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University; Beijing Ophthalmology & Visual Sciences Key Laboratory, Beijing, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
9
interventional trials for this specific condition
9 interventional trials matched this specific condition name; 3 currently recruiting in our sample.
Data as of 27 July 2026
9 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 91.2th percentile).
medium confidence · 91.2th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
9 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07586306·NOT YET RECRUITING·A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD)
Conditions: Bietti Crystalline Dystrophy·Matched via name phrase
- NCT07653971·NOT YET RECRUITING·ZVS101e in Patients With Bietti's Crystalline Dystrophy
Conditions: Bietti's Crystalline Dystrophy · Bietti Crystalline Corneoretinal Dystrophy·Matched via name phrase
- NCT07307469·ENROLLING BY INVITATION·Compassionate Administration of ZVS101e for Extended Treatment
Conditions: Bietti Crystalline Corneoretinal Dystrophy·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Bietti crystalline dystrophy" OR "Bietti crystalline corneoretinal dystrophy" OR "Bietti crystalline retinopathy"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Bietti crystalline dystrophy" OR "Bietti crystalline corneoretinal dystrophy" OR "Bietti crystalline retinopathy" OR "CYP4V2"
Recall-expansion terms: CYP4V2
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 9 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: BCD
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T00:04:22.953Z
